YU68600A - Upotreba hemopreventivnog agensa u proizvodnji farmaceutskog preparata za upotrebu u prevenciji karcinogeneze prostate - Google Patents

Upotreba hemopreventivnog agensa u proizvodnji farmaceutskog preparata za upotrebu u prevenciji karcinogeneze prostate

Info

Publication number
YU68600A
YU68600A YU68600A YU68600A YU68600A YU 68600 A YU68600 A YU 68600A YU 68600 A YU68600 A YU 68600A YU 68600 A YU68600 A YU 68600A YU 68600 A YU68600 A YU 68600A
Authority
YU
Yugoslavia
Prior art keywords
prostate
prostate cancer
chemopreventive agent
cancerogenesis
prevention
Prior art date
Application number
YU68600A
Other languages
English (en)
Inventor
Mitchell S. Steiner
Sharon Raghow
Original Assignee
The University Of Tennessee Research Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tennessee Research Corporation filed Critical The University Of Tennessee Research Corporation
Publication of YU68600A publication Critical patent/YU68600A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pronalazak obezbeduje upotrebu hemopreventivnog agensa, posebno toremifena i njegovih analoga ili metabolita, u proizvodnji farmaceutskog preparata za upotrebu radi prevencije, sprečavanja recidiva, suzbijanja ili inhibicije razvoja kancerogeneze prostate. Farmaceutski preparat proizveden upotrebom označenog hemopreventivnog agensa obezbedjuje bezbedno i efektivno suzbijanje ili inhibiciju latentnog kancera prostate i posebno je koristan kada se primenjuje na subjekte koji imaju povišen rizik od razvoja kancera prostate, na primer one koji imaju benignu hiperplaziju prostate, intraepitelijalnu neoplaziju prostate (PIN), ili abnormalno visoki nivo cirkulišućeg prostata-specifičnog antitela (PSA), ili onih koji imaju porodičnu istoriju kancera prostate.[This invention provides the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis. The present invention provides a safe and effective method for suppressing or inhibiting latent prostate cancer and is particularly useful for treating subjects having an elevated risk of developing prostate cancer, for example, those having benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), or who have a family history of prostate cancer.
YU68600A 1998-05-07 1999-05-07 Upotreba hemopreventivnog agensa u proizvodnji farmaceutskog preparata za upotrebu u prevenciji karcinogeneze prostate YU68600A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8460298P 1998-05-07 1998-05-07

Publications (1)

Publication Number Publication Date
YU68600A true YU68600A (sh) 2003-12-31

Family

ID=22186034

Family Applications (1)

Application Number Title Priority Date Filing Date
YU68600A YU68600A (sh) 1998-05-07 1999-05-07 Upotreba hemopreventivnog agensa u proizvodnji farmaceutskog preparata za upotrebu u prevenciji karcinogeneze prostate

Country Status (26)

Country Link
US (1) US6265448B1 (sh)
EP (3) EP1003496B1 (sh)
JP (2) JP4482229B2 (sh)
AT (1) ATE283043T1 (sh)
AU (1) AU761435B2 (sh)
BG (1) BG65597B1 (sh)
CA (1) CA2323809C (sh)
CZ (1) CZ300960B6 (sh)
DE (2) DE69922131T2 (sh)
DK (1) DK1003496T3 (sh)
EA (1) EA003466B1 (sh)
ES (1) ES2145730T3 (sh)
HR (1) HRP20000729A2 (sh)
HU (1) HUP0102068A3 (sh)
IL (3) IL138437A0 (sh)
IS (2) IS2213B (sh)
NO (1) NO20005625L (sh)
NZ (1) NZ527522A (sh)
PL (1) PL207462B1 (sh)
PT (1) PT1003496E (sh)
SI (1) SI1003496T1 (sh)
SK (1) SK16642000A3 (sh)
TR (1) TR200003269T2 (sh)
UA (1) UA74532C2 (sh)
WO (1) WO1999056739A1 (sh)
YU (1) YU68600A (sh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
DE69922131T2 (de) * 1998-05-07 2005-11-24 The University Of Tennessee Research Corp., Knoxville Medikament zur behandlung intraepithelialer prostataneoplasie
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US6413534B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
WO2001017480A2 (en) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US6642274B1 (en) 1999-09-09 2003-11-04 Gary W. Neal Methods and compositions for preventing and treating prostate disorders
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
ES2319785T3 (es) 2001-11-29 2009-05-12 Gtx, Inc. Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos.
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US20050208159A1 (en) * 2004-03-16 2005-09-22 Kang Kyung S Phytoestrogenic composition comprising an extract of chinese licorice root, liquiritin or isoliquiritin
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
USD969722S1 (en) 2021-09-28 2022-11-15 Wagner Delima Stabilizing wedge pad

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
AU687767B2 (en) * 1992-12-01 1998-03-05 Oy Biotie Therapies Ltd Syndecan stimulation of cellular differentiation
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
JPH08510451A (ja) 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
CZ285508B6 (cs) 1993-08-09 1999-08-11 Edward Baral Použití trifenylethylenových antiestrogenů pro zvyšování citlivosti rakovinných buněk k lyzi zprostředkované zabíječskými buňkami
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
ZA984650B (en) 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
DE69922131T2 (de) * 1998-05-07 2005-11-24 The University Of Tennessee Research Corp., Knoxville Medikament zur behandlung intraepithelialer prostataneoplasie

Also Published As

Publication number Publication date
JP2002513755A (ja) 2002-05-14
DE69922131T2 (de) 2005-11-24
IL138437A (en) 2008-12-29
EA003466B1 (ru) 2003-06-26
CA2323809C (en) 2007-09-18
TR200003269T2 (tr) 2001-02-21
CZ300960B6 (cs) 2009-09-23
EP1003496A1 (en) 2000-05-31
JP2008163048A (ja) 2008-07-17
PT1003496E (pt) 2005-04-29
US6265448B1 (en) 2001-07-24
ES2145730T3 (es) 2005-06-16
EP1475087A2 (en) 2004-11-10
NO20005625D0 (no) 2000-11-07
SK16642000A3 (sk) 2002-08-06
EP1003496B1 (en) 2004-11-24
AU4072699A (en) 1999-11-23
BG65597B1 (bg) 2009-02-27
DE1003496T1 (de) 2000-11-02
IL138437A0 (en) 2001-10-31
HUP0102068A3 (en) 2002-11-28
EP2277514A1 (en) 2011-01-26
ATE283043T1 (de) 2004-12-15
UA74532C2 (en) 2006-01-16
CA2323809A1 (en) 1999-11-11
EP1475087A3 (en) 2007-07-11
HUP0102068A2 (hu) 2002-05-29
IS5700A (is) 2000-11-01
EA200000100A1 (ru) 2000-08-28
NO20005625L (no) 2001-01-05
IL193231A0 (en) 2009-02-11
CZ20004118A3 (cs) 2002-07-17
JP4482229B2 (ja) 2010-06-16
WO1999056739A1 (en) 1999-11-11
DE69922131D1 (de) 2004-12-30
NZ527522A (en) 2005-04-29
SI1003496T1 (en) 2005-10-31
IS2213B (is) 2007-03-15
HRP20000729A2 (en) 2001-06-30
IS8354A (is) 2006-03-15
PL344000A1 (en) 2001-09-10
AU761435B2 (en) 2003-06-05
ES2145730T1 (es) 2000-07-16
PL207462B1 (pl) 2010-12-31
BG105022A (bg) 2001-07-31
DK1003496T3 (da) 2005-04-04

Similar Documents

Publication Publication Date Title
YU68600A (sh) Upotreba hemopreventivnog agensa u proizvodnji farmaceutskog preparata za upotrebu u prevenciji karcinogeneze prostate
MXPA02004676A (es) Un metodo para quimioprevencion de cancer de prostata.
PL1624878T3 (pl) Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
BG97678A (en) Beta -carotene and/or vitamin e therapy for inhibition of major vascular events
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
NO971349L (no) Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
DK0871468T3 (da) Fremgangsmåder til behandling af prostatacancer med LHRH-antagonister
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
MY111188A (en) Improvements in or relating to benzothiophenes.
Tsukamoto et al. A five‐alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats
FI955154A (fi) Viruskombinantteja ja niiden käyttö geeniterapiassa
Spencer Hydroquinone Bleaching: Submitted for publication March 6, 1961. This study was approved by the Veterans Administration Hospital, Danville, Ill. From the Department of Dermatology, Northwestern University Medical School, Chicago.
Kim et al. Inhibition of UVB‐Induced Skin Damage by Exopolymers from Aureobasidium pullulans SM‐2001 in Hairless Mice
FR2675997B1 (fr) Composition topique anti radicaux libres a base de superoxyde-dismutase et d'un derive phosphonique.
HUP0001063A2 (hu) Zöld porfirinek alkalmazása ateroszklerózis kezelésére szolgáló gyógyászati készítmények előállítására
Dnistrian et al. Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy
Pettersson et al. Cohort study of the long-term effect of irradiation for carcinoma of the uterine cervix: second primary malignancies in the pelvic organs in women irradiated for cervical carcinoma at Radiumhemmet 1914–1965
McLaughlin et al. Occupational risks for male breast cancer in Sweden.
EP1545479A4 (en) EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS
Strum Ranitidine
Shirai et al. Enhancing effect of cadmium on rat ventral prostate carcinogenesis induced by 3, 2′‐dimethyl‐4‐aminobiphenyl
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer